JW (Cayman) Therapeutics Management
Management criteria checks 3/4
JW (Cayman) Therapeutics' CEO is James Li, appointed in Feb 2016, has a tenure of 8.17 years. total yearly compensation is CN¥31.12M, comprised of 10.8% salary and 89.2% bonuses, including company stock and options. directly owns 5.15% of the company’s shares, worth HK$35.94M. The average tenure of the management team and the board of directors is 2.3 years and 3.8 years respectively.
Key information
James Li
Chief executive officer
CN¥31.1m
Total compensation
| CEO salary percentage | 10.8% |
| CEO tenure | 8.2yrs |
| CEO ownership | 5.1% |
| Management average tenure | 2.3yrs |
| Board average tenure | 3.8yrs |
Recent management updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2023 | n/a | n/a | -CN¥768m |
| Sep 30 2023 | n/a | n/a | -CN¥783m |
| Jun 30 2023 | n/a | n/a | -CN¥797m |
| Mar 31 2023 | n/a | n/a | -CN¥822m |
| Dec 31 2022 | CN¥31m | CN¥3m | -CN¥846m |
| Sep 30 2022 | n/a | n/a | -CN¥849m |
| Jun 30 2022 | n/a | n/a | -CN¥851m |
| Mar 31 2022 | n/a | n/a | -CN¥777m |
| Dec 31 2021 | CN¥41m | CN¥2m | -CN¥702m |
| Sep 30 2021 | n/a | n/a | -CN¥998m |
| Jun 30 2021 | n/a | n/a | -CN¥1b |
| Mar 31 2021 | n/a | n/a | -CN¥1b |
| Dec 31 2020 | CN¥99m | CN¥3m | -CN¥2b |
| Sep 30 2020 | n/a | n/a | -CN¥1b |
| Jun 30 2020 | n/a | n/a | -CN¥925m |
| Mar 31 2020 | n/a | n/a | -CN¥779m |
| Dec 31 2019 | CN¥4m | CN¥3m | -CN¥633m |
Compensation vs Market: James's total compensation ($USD4.30M) is above average for companies of similar size in the Hong Kong market ($USD233.25K).
Compensation vs Earnings: James's compensation has been consistent with company performance over the past year.
CEO
James Li (59 yo)
8.2yrs
Tenure
CN¥31,118,000
Compensation
Dr. Yiping Li, M.D., also known as James, has been a Partner of KPCB China Fund, which is an affiliate of TDF Capital China II, LP, since 2009. He serves as Co-founder and Executive Chairman at JW (Cayman)...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-founder | 8.2yrs | CN¥31.12m | 5.15% CN¥ 35.9m | |
| Senior Vice President of Tech Operations | 1.8yrs | no data | no data | |
| Senior VP & Chief Scientific Officer | 2.3yrs | no data | no data | |
| Senior Vice President of Corporate Development | 2.3yrs | no data | no data | |
| Senior VP & Chief Commercial Officer | no data | no data | no data | |
| Senior Advisor & Acting Chief Medical Officer | no data | no data | no data | |
| Company Secretary | 2.3yrs | no data | no data |
2.3yrs
Average Tenure
49yo
Average Age
Experienced Management: 2126's management team is considered experienced (2.3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-founder | 6.4yrs | CN¥31.12m | 5.15% CN¥ 35.9m | |
| Independent Non-Executive Director | 1.1yrs | no data | no data | |
| Non-Executive Director | 3.8yrs | CN¥331.00k | 1.43% CN¥ 10.0m | |
| Independent Non-Executive Director | 3.5yrs | CN¥224.00k | no data | |
| Non-Executive Director | less than a year | no data | no data | |
| Independent Non-Executive Director | 3.5yrs | CN¥323.00k | no data | |
| Independent Non-Executive Director | 4.4yrs | CN¥331.00k | no data | |
| Non-Executive Director | 3.9yrs | no data | no data | |
| Independent Non-Executive Director | 3.9yrs | CN¥331.00k | no data |
3.8yrs
Average Tenure
56yo
Average Age
Experienced Board: 2126's board of directors are considered experienced (3.8 years average tenure).